Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/07/24
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024GlobeNewsWire • 10/15/24
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health CongressGlobeNewsWire • 10/11/24
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory BoardGlobeNewsWire • 10/08/24
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/08/24
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024GlobeNewsWire • 08/02/24
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial OfficerGlobeNewsWire • 06/27/24
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY TrialGlobeNewsWire • 05/16/24
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/13/24
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 03/19/24
Here's Why Momentum in Tourmaline Bio, Inc. (TRML) Should Keep goingZacks Investment Research • 03/15/24
What Makes Tourmaline Bio, Inc. (TRML) a Good Fit for 'Trend Investing'Zacks Investment Research • 02/08/24
Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceGlobeNewsWire • 02/01/24
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 01/29/24
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)GlobeNewsWire • 01/08/24
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 MillionGlobeNewsWire • 10/19/23